UCSF Helen Diller Comprehensive Cancer Center

University of California San Francisco

San Francisco, CA

Sorting 1 by

Accepting patients

LANTERN

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Radiation
  • Phase 2